Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04746612
Other study ID # HH30134-G101
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date April 8, 2021
Est. completion date March 24, 2023

Study information

Verified date December 2022
Source Haihe Biopharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and to determine the maximum tolerable dose (MTD) and/or recommended phase 2 dose (RP2D) of HH30134 administered orally on a continuous once daily (QD) schedule in adults patients with advanced solid tumors.


Description:

Study population This is a global study involving multi-countries and multi-sites. Approximately 60 patients will be enrolled from participation institutions from different countries. Enrollment in dose-escalation phase must have histologically or cytologically confirmed advanced solid tumors that have recurred or progressed following the last line of therapy and at least one prior standard of care regimens, or tumor for which there is no approved therapy, or for which standard therapy is unsuitable or refused. Enrollment in dose-expansion phase will be patients with selected solid tumors including but not limited to NSCLC and mCRC.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date March 24, 2023
Est. primary completion date March 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Provision of signed and dated informed consent form. - Stated willingness to comply with all study procedures and availability for the duration of the study. - Male and female patients = 18 years of age (or having reached the age of majority according to local laws and regulations, if the age is > 18 years) - Patients must have histologically or cytologically confirmed advanced solid tumors - Predicted life expectancy of = 3 months - Eastern Cooperative Oncology Group (ECOG) performance status = 1 - Availability of archival tissue within three years or fresh tumor biopsy sample - Patients must have adequate hepatic and renal function Exclusion Criteria: - Patient has received any anticancer therapy (including chemotherapy, targeted therapy, hormonal therapy, biotherapy, immunotherapy, or other investigational agents.) within 28 days or 5 times of half-lives (whichever is shorter) prior to the first dose of the study treatment. - Radical radiation therapy (including radiation therapy for over 25% bone marrow) within 4 weeks prior to the first dose of the investigational product or received local palliative radiation therapy for bone metastases within 2 weeks. - Any toxicities from prior treatment that have not recovered to baseline or = CTCAE v5.0 Grade 1 before the start of study treatment, with exception of hair loss. - Patients who have symptomatic CNS metastasis which is neurologically unstable or those who have CNS disease requiring increase in the dose of steroid. - Major surgery or had significant traumatic injury within 28 days prior to the first dose of the investigational product or has not recovered from major side effects. - Known HIV infection with a history of acquired immunodeficiency syndrome (AIDS)- defining opportunity infection within the past 12months; active hepatitis B and hepatitis C. Patients whose test results meet one of the following will not be enrolled: - Patient is currently receiving or has received systemic corticosteroids = 2 weeks prior to starting study treatment, or who have not fully recovered from side effects of such treatment. - Gastrointestinal condition which could impair absorption of study medication. - Patients with clinically significant cardiovascular disease - Any diseases or medical conditions, at the Investigator's discretion, that may be unstable or influence their safety or study compliance, including organ transplantation, abuse of psychotropic medication, alcohol abuse or history of drug abuse. - Other serious illness or medical conditions at the Investigator's discretion, that may influence study results, including but not limited to serious infection, diabetes, cardiovascular and cerebrovascular diseases or lung disease. - Pregnant or breast-feeding patients. Pregnancy refers to the state of a woman between fertilization and the end of pregnancy confirmed by a positive laboratory hCG test (> 5 mIU/mL). Breast-feeding woman can become eligible for this study if she stops breast-feeding, however, cannot restart the breast-feeding on/after the completion of the study treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HH30134
HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors

Locations

Country Name City State
Australia Blacktown Hospital Blacktown
Australia Scientia Clinical Research Randwick
China Sun Yat-sen University Cancer Center Guangzhou
China Fudan University Zhongshan Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Haihe Biopharma Co., Ltd.

Countries where clinical trial is conducted

Australia,  China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicities(DLT) Incidence rate of dose limiting toxicities(DLT) 12 months
Primary Maximum Tolerated Dose To determine the maximum tolerable dose 12 months
Secondary Pharmacokinetic(PK) measures - Plasma concentration-time Area Under the Curve Measure the HH30134 concentration in blood plasma as a function of time 12 months
Secondary Pharmacokinetic(PK) measures - Cmax Measure the maximum plasma concentration of HH30134 12 months
Secondary Pharmacokinetic(PK) measures - Tmax Measure of time to reach maximum plasma concentration after administration of HH30134 12 months
Secondary Pharmacokinetic(PK) measures - CL/F Measure apparent total clearance of HH30134 from plasma after administration 12 months
Secondary Pharmacokinetic(PK) measures - Vz/F Measure apparent volume of distribution during terminal phase after administration of HH30134 12 months
Secondary Pharmacokinetic(PK) measures - terminal half-life(T1/2) Measure elimination half-life of HH30134 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1